{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:57:59Z","timestamp":1781272679912,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006402","name":"Fasa University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12116-y","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:16:07Z","timestamp":1781270167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRISPR\/Cas9-mediated knockout of TopBP1 shifts the Bax\/Bcl-2 balance toward apoptosis in MCF7 breast cancer cells"],"prefix":"10.1007","volume":"53","author":[{"given":"Samane","family":"Taheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Azarpira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Mahmoodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Gila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahintaj","family":"Dara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"13","key":"12116_CR1","first-page":"1631","volume":"56","author":"B Sajer","year":"2025","unstructured":"Sajer B, Al-shamer AS (2025) Breast Cancer: Classification, Risk Factors, and Current Therapeutic Strategies Challenge and the Emerging Role of Natural Products. Egypt J Veterinary Sci 56(13):1631\u20131641","journal-title":"Egypt J Veterinary Sci"},{"issue":"12","key":"12116_CR2","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1080\/09603123.2025.2492826","volume":"35","author":"NA Elhawary","year":"2025","unstructured":"Elhawary NA, Ekram SN, Sembawa HA, Tashkandi E, Bannani S, Azher ZA, Abumansour IS, Almuqati RM, Attieh R, Sindi IA, Almutrafi M (2025) Descriptive epidemiology of female breast cancer around the world: incidence, mortality, and sociodemographic risks and disparities. Int J Environ Health Res 35(12):3648\u20133662","journal-title":"Int J Environ Health Res"},{"issue":"3","key":"12116_CR3","first-page":"104","volume":"1","author":"A Faramarzi","year":"2021","unstructured":"Faramarzi A, Jahromi MG, Ashourzadeh S, Jalilian N (2021) Metastatic and pathophysiological characteristics of breast cancer with emphasis on hereditary factors. Cent Asian J Med Pharm Sci Innov 1(3):104\u2013113","journal-title":"Cent Asian J Med Pharm Sci Innov"},{"issue":"1","key":"12116_CR4","doi-asserted-by":"publisher","first-page":"107327481984843","DOI":"10.1177\/1073274819848432","volume":"26","author":"H Joulaei","year":"2019","unstructured":"Joulaei H, Zarei N (2019) Women\u2019s cancer care in Iran. Cancer Control 26(1):1073274819848432","journal-title":"Cancer Control"},{"issue":"6","key":"12116_CR5","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s12282-025-01779-3","volume":"32","author":"X Li","year":"2025","unstructured":"Li X, Huang T (2025) Advances in the intrinsic signaling pathway interactions and clinical translation of HR+\/HER2\u2009+\u2009breast cancer. Breast Cancer 32(6):1216\u20131243","journal-title":"Breast Cancer"},{"issue":"8","key":"12116_CR6","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/cancers16081483","volume":"16","author":"A Szulc","year":"2024","unstructured":"Szulc A, Wo\u017aniak M (2024) Targeting pivotal hallmarks of cancer for enhanced therapeutic strategies in triple-negative breast cancer treatment\u2014in vitro, in vivo and clinical trials literature review. Cancers 16(8):1483","journal-title":"Cancers"},{"issue":"8","key":"12116_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3390\/jpm11080808","volume":"11","author":"A Burguin","year":"2021","unstructured":"Burguin A, Diorio C, Durocher F (2021) Breast cancer treatments: updates and new challenges. J personalized Med 11(8):808","journal-title":"J personalized Med"},{"issue":"4","key":"12116_CR8","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/ijms23042288","volume":"23","author":"KH Lau","year":"2022","unstructured":"Lau KH, Tan AM, Shi Y (2022) New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci 23(4):2288","journal-title":"Int J Mol Sci"},{"issue":"19","key":"12116_CR9","doi-asserted-by":"publisher","first-page":"11046","DOI":"10.3390\/ijms231911046","volume":"23","author":"Y Wang","year":"2022","unstructured":"Wang Y, Minden A (2022) Current molecular combination therapies used for the treatment of breast cancer. Int J Mol Sci 23(19):11046","journal-title":"Int J Mol Sci"},{"issue":"3","key":"12116_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/pharmaceutics12030233","volume":"12","author":"C Roma-Rodrigues","year":"2020","unstructured":"Roma-Rodrigues C, Rivas-Garc\u00eda L, Baptista PV, Fernandes AR (2020) Gene therapy in cancer treatment: why go nano? Pharmaceutics 12(3):233","journal-title":"Pharmaceutics"},{"issue":"3","key":"12116_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/ph17030333","volume":"17","author":"T Ismail","year":"2024","unstructured":"Ismail T, Alzneika S, Riguene E, Al-Maraghi S, Alabdulrazzak A, Al-Khal N, Fetais S, Thanassoulas A, AlFarsi H, Nomikos M (2024) BRCA1 and its vulnerable C-terminal BRCT domain: structure, function, genetic mutations and links to diagnosis and treatment of breast and ovarian cancer. Pharmaceuticals 17(3):333","journal-title":"Pharmaceuticals"},{"issue":"1","key":"12116_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/0008-5472.CAN-15-3032","volume":"77","author":"DW Kang","year":"2017","unstructured":"Kang DW, Lee SW, Hwang WC, Lee BH, Choi Y-S, Suh Y-A et al (2017) Phospholipase D1 acts through Akt\/TopBP1 and RB1 to regulate the E2F1-dependent apoptotic program in cancer cells. Cancer Res 77(1):142\u2013152","journal-title":"Cancer Res"},{"key":"12116_CR13","doi-asserted-by":"publisher","first-page":"1397303","DOI":"10.3389\/fimmu.2024.1397303","volume":"15","author":"Y Gao","year":"2024","unstructured":"Gao Y, Qiao X, Liu Z, Zhang W (2024) The role of E2F2 in cancer progression and its value as a therapeutic target. Front Immunol 15:1397303","journal-title":"Front Immunol"},{"issue":"12","key":"12116_CR14","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1038\/s41418-022-01036-6","volume":"29","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Huang X, Zhu D, Wei M, Luo J, Yu S et al (2022) Deubiquitinase OTUD6A promotes breast cancer progression by increasing TopBP1 stability and rendering tumor cells resistant to DNA-damaging therapy. Cell Death Differ 29(12):2531\u20132544","journal-title":"Cell Death Differ"},{"issue":"3","key":"12116_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s42764-022-00072-3","volume":"3","author":"Z Yan","year":"2022","unstructured":"Yan Z, Ge X, Wang J, Xu F, Li M, Liu X et al (2022) The impact of TOPBP1 mutations in human cancers on the DNA damage response. Genome Instability Disease 3(3):144\u2013162","journal-title":"Genome Instability Disease"},{"issue":"5","key":"12116_CR16","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.3390\/ijms24054684","volume":"24","author":"J Fahrer","year":"2023","unstructured":"Fahrer J, Christmann M (2023) DNA alkylation damage by nitrosamines and relevant DNA repair pathways. Int J Mol Sci 24(5):4684","journal-title":"Int J Mol Sci"},{"issue":"3","key":"12116_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/osi2.1102","volume":"18","author":"Y Obayashi","year":"2021","unstructured":"Obayashi Y, Fujikane R, Morita S, Uechi Y, Hiraki A, Hidaka M (2021) Suppression of TopBP1 function increases the efficacy of chemotherapeutic treatments by enhancing the induction of apoptosis. Oral Sci Int 18(3):209\u2013216","journal-title":"Oral Sci Int"},{"key":"12116_CR18","doi-asserted-by":"publisher","first-page":"1342193","DOI":"10.3389\/fgeed.2024.1342193","volume":"6","author":"A Macarr\u00f3n Palacios","year":"2024","unstructured":"Macarr\u00f3n Palacios A, Korus P, Wilkens BG, Heshmatpour N, Patnaik SR (2024) Revolutionizing in vivo therapy with CRISPR\/Cas genome editing: breakthroughs, opportunities and challenges. Front Genome Editing 6:1342193","journal-title":"Front Genome Editing"},{"key":"12116_CR19","doi-asserted-by":"publisher","unstructured":"Gulati P, Singh CV (2024) The Crucial Role of Molecular Biology in Cancer Therapy: A Comprehensive Review. Cureus. ;16(1).e52246 https:\/\/doi.org\/10.7759\/cureus.52246","DOI":"10.7759\/cureus.52246"},{"key":"12116_CR20","doi-asserted-by":"crossref","unstructured":"Lapee-e V, Nuanualsuwan S, Hongtanee L, Yakoh A (2025) based CRISPR-Cas diagnostics: A comprehensive review of advances and applications in disease detection. Microchem J. 211: 113055","DOI":"10.1016\/j.microc.2025.113055"},{"issue":"8","key":"12116_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","volume":"20","author":"A Pickar-Oliver","year":"2019","unstructured":"Pickar-Oliver A, Gersbach CA (2019) The next generation of CRISPR\u2013Cas technologies and applications. Nat Rev Mol Cell Biol 20(8):490\u2013507","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"12116_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/genes12050723","volume":"12","author":"M Ahmed","year":"2021","unstructured":"Ahmed M, Daoud GH, Mohamed A, Harati R (2021) New insights into the therapeutic applications of CRISPR\/Cas9 genome editing in breast cancer. Genes 12(5):723","journal-title":"Genes"},{"issue":"3","key":"12116_CR23","doi-asserted-by":"publisher","first-page":"e3003052","DOI":"10.1371\/journal.pbio.3003052","volume":"23","author":"S Huang","year":"2025","unstructured":"Huang S, Soto AM, Sonnenschein C (2025) The end of the genetic paradigm of cancer. PLoS Biol 23(3):e3003052","journal-title":"PLoS Biol"},{"issue":"3","key":"12116_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321(3):288\u2013300","journal-title":"JAMA"},{"issue":"3","key":"12116_CR25","doi-asserted-by":"publisher","first-page":"e36905","DOI":"10.1097\/MD.0000000000036905","volume":"103","author":"EI Obeagu","year":"2024","unstructured":"Obeagu EI, Obeagu GU (2024) Breast cancer: A review of risk factors and diagnosis. Medicine 103(3):e36905","journal-title":"Medicine"},{"issue":"5","key":"12116_CR26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/jnci\/djz196","volume":"112","author":"JF Dekkers","year":"2020","unstructured":"Dekkers JF, Whittle JR, Vaillant F, Chen H-R, Dawson C, Liu K et al (2020) Modeling breast cancer using CRISPR-Cas9\u2013mediated engineering of human breast organoids. JNCI: J Natl Cancer Inst 112(5):540\u2013544","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"12116_CR27","doi-asserted-by":"crossref","unstructured":"Umesh RM, Lahiri M (2022) Overexpression of TopBP1 leads to transformation with a TP53 mutation of non-tumorigenic breast epithelial cells. bioRxiv. 6: 2022\u20132004","DOI":"10.1101\/2022.04.05.487132"},{"issue":"1","key":"12116_CR28","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1038\/s41467-022-31865-5","volume":"13","author":"M De Marco Zompit","year":"2022","unstructured":"De Marco Zompit M, Esteban MT, Mooser C, Adam S, Rossi SE, Jeanrenaud A, Leimbacher PA, Fink D, Shorrocks AM, Blackford AN, Durocher D (2022) The CIP2A-TOPBP1 complex safeguards chromosomal stability during mitosis. Nat Commun 13(1):4143","journal-title":"Nat Commun"},{"key":"12116_CR29","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.1007\/s11033-012-1622-z","volume":"39","author":"E Forma","year":"2012","unstructured":"Forma E, Krzeslak A, Bernaciak M, Romanowicz-Makowska H, Brys M (2012) Expression of TopBP1 in hereditary breast cancer. Mol Biol Rep 39:7795\u20137804","journal-title":"Mol Biol Rep"},{"key":"12116_CR30","doi-asserted-by":"publisher","unstructured":"LiuK, Graves JD, Lin F-T, Lin W-C (2021) Overexpression of TopBP1, a canonical ATR\/Chk1 activator, paradoxically hinders ATR\/Chk1 activation in cancer. J Biol Chem. 10100382; 296 https:\/\/doi.org\/10.1016\/j.jbc.2021.100382","DOI":"10.1016\/j.jbc.2021.100382"},{"key":"12116_CR31","doi-asserted-by":"publisher","unstructured":"LvY, Huo Y, Yu X, Liu R, Zhang S, Zheng X et al (2016) TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53. Drug Des Devel Ther. 10: 3053\u20133064 https:\/\/doi.org\/10.2147\/DDDT.S90705","DOI":"10.2147\/DDDT.S90705"},{"issue":"1","key":"12116_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","volume":"147","author":"X Zhang","year":"2023","unstructured":"Zhang X (2023) Molecular classification of breast cancer: relevance and challenges. Arch Pathol Lab Med 147(1):46\u201351","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"12116_CR33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1101\/gad.1180204","volume":"18","author":"K Liu","year":"2004","unstructured":"Liu K, Luo Y, Lin F-T, Lin W-C (2004) TopBP1 recruits Brg1\/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev 18(6):673\u2013686","journal-title":"Genes Dev"},{"key":"12116_CR34","doi-asserted-by":"publisher","first-page":"e44353","DOI":"10.7554\/eLife.44353","volume":"8","author":"N Bigot","year":"2019","unstructured":"Bigot N, Day M, Baldock RA, Watts FZ, Oliver AW, Pearl LH (2019) Phosphorylation-mediated interactions with TOPBP1 couple 53BP1 and 9-1-1 to control the G1 DNA damage checkpoint. Elife 8:e44353","journal-title":"Elife"},{"key":"12116_CR35","doi-asserted-by":"crossref","unstructured":".Umesh RM, Lahiri M Overexpression of TopBP1 leads to transformation with a TP53 mutation of non-tumorigenic breast epithelial cells. bioRxiv. 2022:2022.04.","DOI":"10.1101\/2022.04.05.487132"},{"key":"12116_CR36","doi-asserted-by":"crossref","unstructured":"Lin F-T, Liu K, Garan LAW, Folly-Kossi H, Song Y, Lin S-J et al (2023) A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors. Proceedings of the National Academy of Sciences. ;120(44):e2307793120","DOI":"10.1073\/pnas.2307793120"},{"issue":"10","key":"12116_CR37","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1128\/MCB.01140-08","volume":"29","author":"K Liu","year":"2009","unstructured":"Liu K, Bellam N, Lin H-Y, Wang B, Stockard CR, Grizzle WE et al (2009) Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer. Mol Cell Biol 29(10):2673\u20132693","journal-title":"Mol Cell Biol"},{"issue":"22","key":"12116_CR38","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1128\/MCB.05574-11","volume":"31","author":"K Liu","year":"2011","unstructured":"Liu K, Ling S, Lin W-C (2011) TopBP1 mediates mutant p53 gain of function through NF-Y and p63\/p73. Mol Cell Biol 31(22):4464\u20134481","journal-title":"Mol Cell Biol"},{"key":"12116_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2016.10.033","volume":"385","author":"H Wang","year":"2017","unstructured":"Wang H, Sun W (2017) CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation. Cancer Lett 385:137\u2013143","journal-title":"Cancer Lett"},{"key":"12116_CR40","doi-asserted-by":"publisher","unstructured":"YangM, Zeng C, Li P, Qian L, Ding B, Huang L et al (2019) Impact of CXCR4 and CXCR7 knockout by CRISPR\/Cas9 on the function of triple-negative breast cancer cells. OncoTargets therapy. 12: 3849\u20133858 https:\/\/doi.org\/10.2147\/OTT.S195661","DOI":"10.2147\/OTT.S195661"},{"key":"12116_CR41","doi-asserted-by":"publisher","first-page":"103278","DOI":"10.1016\/j.dnarep.2022.103278","volume":"111","author":"Z Fang","year":"2022","unstructured":"Fang Z, Gong C, Ye Z, Wang W, Zhu M, Hu Y et al (2022) TOPBP1 regulates resistance of gastric cancer to oxaliplatin by promoting transcription of PARP1. DNA Repair 111:103278","journal-title":"DNA Repair"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12116-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12116-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12116-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:16:12Z","timestamp":1781270172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12116-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12116"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12116-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}],"article-number":"932"}}